
Biogen comes under renewed fire as a leading Alzheimer's expert raises serious questions about the aducanumab data
Biogen execs have lots of explaining to do later this week if they expect to hold on to the massive upswing in market cap $BIIB the big biotech experienced with their upbeat assessment of their chances of winning an FDA approval of aducanumab as the first disease-modifying therapy for Alzheimer’s — widely considered the golden ticket in R&D today for a megablockbuster market.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,700+ biopharma pros reading Endpoints daily — and it's free.